Skyrizi PI: Understanding the Prescribing Information

When it comes to prescribing medications, healthcare professionals must have a comprehensive understanding of the prescribing information (PI) for each drug. In this article, we will delve into the prescribing information for Skyrizi, a prescription medication used to treat certain autoimmune conditions.

What is Skyrizi?

Skyrizi is a medication that falls under the class of interleukin inhibitors. It is primarily prescribed for adults with moderate to severe plaque psoriasis, a chronic autoimmune condition characterized by red, scaly patches on the skin. Skyrizi functions by targeting specific proteins in the body that are involved in the inflammatory response associated with psoriasis.

• Skyrizi is specifically designed to block interleukin-23 (IL-23) which is a key player in the inflammation process in psoriasis.
• This medication helps reduce the symptoms of psoriasis by decreasing inflammation in the skin.
• Clinical trials have shown that Skyrizi is effective in improving skin clearance and reducing the severity of symptoms in patients with plaque psoriasis.

How is Skyrizi administered?

Skyrizi is administered through subcutaneous injection, where it is injected beneath the skin. The frequency of injections varies depending on the dosing schedule recommended by the healthcare provider. Proper training on injection techniques is crucial for patients to ensure accurate administration and minimize the risk of complications.

• Patients should receive thorough training from a healthcare professional on how to self-administer Skyrizi injections.
• The injections are typically given every 12 weeks after the initial doses, but the dosing schedule may be adjusted based on individual patient response.
• It is important for patients to rotate injection sites to prevent injection site reactions and ensure optimal absorption of the medication.

What are the potential side effects of Skyrizi?

As with any medication, Skyrizi may cause side effects in some patients. Common side effects associated with Skyrizi include:

• Injection site reactions, such as redness, swelling, or pain, which are usually mild and temporary.
• Upper respiratory infections, such as the common cold or sinusitis.
• Headache, which may occur during the initial stages of treatment but often subsides over time.
• Fatigue, which may affect some patients but typically improves with continued use.
• Diarrhea, which is a less common side effect but should be reported to a healthcare provider if persistent.

It is essential for patients to communicate any side effects they experience to their healthcare provider, as some may require medical attention. Regular monitoring by a healthcare provider is also necessary to ensure the effectiveness and safety of Skyrizi.

What are the contraindications and precautions for Skyrizi?

Before prescribing Skyrizi, healthcare providers must be aware of the contraindications and precautions associated with the medication. Skyrizi should not be used in patients with a known hypersensitivity to any of its ingredients. Additionally, caution should be exercised when prescribing Skyrizi to patients with a history of infections, as the medication may increase the risk of certain infections.

• Healthcare providers should screen patients for tuberculosis (TB) before initiating treatment with Skyrizi, as the medication may increase the risk of TB reactivation.
• Patients with a history of inflammatory bowel disease should be monitored closely while taking Skyrizi, as exacerbation of symptoms may occur.
• Live vaccines should be avoided while on Skyrizi therapy, as the medication may interfere with the vaccine’s effectiveness.

How should Skyrizi be stored?

Skyrizi should be stored in the refrigerator at a temperature between 36°F to 46°F (2°C to 8°C). It should not be frozen, and before use, it should be allowed to reach room temperature for approximately 30 minutes. Once at room temperature, Skyrizi should be used within 4 hours. Any unused medication should be disposed of properly according to local regulations.

• Skyrizi should be stored in its original packaging to protect it from light and moisture.
• Do not shake Skyrizi vigorously, as this may affect its potency and effectiveness.
• Keep Skyrizi out of reach of children and pets to prevent accidental ingestion.

Conclusion

In conclusion, a thorough understanding of the prescribing information for Skyrizi is crucial for healthcare professionals prescribing this medication for moderate to severe plaque psoriasis. By being well-informed about the dosing schedule, administration techniques, potential side effects, contraindications, precautions, and storage guidelines for Skyrizi, healthcare providers can ensure the safe and effective use of this medication in their patients. For any further inquiries about Skyrizi or its prescribing information, please consult a healthcare provider or pharmacist.

Note: This article is for informational purposes only and should not be used as a substitute for professional medical advice. Please consult with a healthcare provider for personalized recommendations regarding the use of Skyrizi or any other medication.

FAQ for Skyrizi Prescribing Information

1. What is Skyrizi used for?

Skyrizi is a medication used to treat adults with moderate to severe plaque psoriasis, a chronic autoimmune condition that causes red, scaly patches on the skin.

1. How is Skyrizi administered?

Skyrizi is administered by subcutaneous injection, typically given every few weeks. Patients should receive proper training on how to administer the injections correctly.

1. What are the potential side effects of Skyrizi?

Common side effects of Skyrizi may include injection site reactions, upper respiratory infections, headache, fatigue, and diarrhea. Patients should report any side effects to their healthcare provider.

1. What are the contraindications and precautions for Skyrizi?

Skyrizi should not be used in patients with known hypersensitivity to any of the ingredients. Healthcare providers should use caution when prescribing Skyrizi to patients with a history of infections.